Zoetis stock is trading -21.25% below its average target price of $210.66 after dropping -2.1% during today's afternoon session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $178.13 to $248.0 per share.
Zoetis's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 1.6%. The stock's short ratio is 2.93. The company's insiders own 0.2% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 95.7%. In conclusion, we believe there is positive market sentiment regarding Zoetis.
Institutions Invested in Zoetis
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-09-30 | Vanguard Group Inc | 9% | 41,246,719 | $6,842,418,189 |
| 2024-09-30 | Blackrock Inc. | 8% | 38,231,711 | $6,342,258,514 |
| 2024-09-30 | State Street Corporation | 4% | 19,779,344 | $3,281,195,364 |
| 2024-09-30 | State Farm Mutual Automobile Insurance Co | 4% | 16,037,603 | $2,660,477,951 |
| 2024-09-30 | Alliancebernstein L.P. | 3% | 15,388,528 | $2,552,802,900 |
| 2024-09-30 | Bank of America Corporation | 3% | 14,358,973 | $2,382,010,022 |
| 2024-09-30 | Morgan Stanley | 3% | 12,042,024 | $1,997,651,354 |
| 2024-09-30 | Geode Capital Management, LLC | 2% | 10,427,760 | $1,729,861,100 |
| 2024-09-30 | Capital World Investors | 1% | 6,683,979 | $1,108,805,272 |
| 2024-09-30 | Polen Capital Management, LLC | 1% | 6,366,653 | $1,056,164,062 |
